Text Size

Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00036088
First received: May 7, 2002
Last updated: July 18, 2006
Last verified: July 2006
History of Changes
  Purpose

The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia


Condition Intervention Phase
Schizophrenia
 Drug: Olanzapine
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Further study details as provided by Eli Lilly and Company:

Estimated Enrollment: 530
Study Start Date: August 2001
Estimated Study Completion Date: July 2002
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion:

  1. You must be between the ages of 18 and 75. If you have reached your 76th birthday, you will not be able to participate
  2. You must have been diagnosed with schizophrenia
  3. You must be able to visit the doctor's office as scheduled for the next 7 months

Exclusion:

  1. You have a serious medical illness, such as heart, liver, or kidney disease (Note: If you are uncertain about a particular condition, discuss it with your doctor.)
  2. You are either pregnant or breastfeeding
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00036088

  Show 60 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
  More Information

No publications provided by Eli Lilly and Company

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00036088     History of Changes
Other Study ID Numbers: 2347, F1D-MC-HGHJ
Study First Received: May 7, 2002
Last Updated: July 18, 2006
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Olanzapine
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
 Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents

ClinicalTrials.gov processed this record on May 21, 2013